Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00333138
Status:
COMPLETED
Last Update Posted:
2017-09-15
First Post:
2006-06-01
Brief Title:
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Double-blind Randomized Placebo-controlled Parallel-group Multicenter Study Evaluating the Safety Tolerability and Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients With Relapsing Multiple Sclerosis Including 18 Month Extension Phase
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluated the safety tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CFTY720D2201E1 | OTHER | Novartis | None |